To prevent the onset of obesity and to improve psychomotor development, it is advisable to start GH therapy as soon as possible, between 3 and 6 months of age, monitoring the glucose profile due to the diabetogenic effect of the GH, and the risk of OSA by polysomnography [13]
We conducted a gap analysis using performance year 2024 data to analyze the overlap of our proposed definition of a beneficiary eligible for Medicare CQMs and the current performance year 2025 methodology used to identify beneficiaries assignable to an ACO
Employers that offer GLP1 coverage through a lifestyle or wellness program, should review it for compliance with HIPAAs healthcontingent wellness rules and the ADAs standards for programs involving medical questions or exams
In the SAVOR study DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased [27]
INT-787 (Next-Gen FXR Agonist) is a compound with enhanced FXR selectivity and solubility compared to OCA and has entered clinical trials for SAH
